Literature DB >> 10606878

A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood.

A Eldor1, R Durst, E Hy-Am, A Goldfarb, S Gillis, E A Rachmilewitz, A Abramov, J MacLouf, Y C Godefray, E De Raucourt, M C Guillin.   

Abstract

A higher than normal incidence of thromboembolic events has been observed in adult patients with beta-thalassaemia major (TM) and certain haemostatic anomalies found in these patients suggest the existence of a chronic hypercoagulable state. Thalassaemic red blood cells (RBC) were demonstrated to facilitate thrombin formation due to altered asymmetry of the membrane phospholipids with enhanced exposure of phosphatidylserine. Since RBC anomalies exist in thalassaemia from the first months of life, we studied markers of hypercoagulability and thrombophilia in 36 adult patients (range 19-38 years) and 26 children (range 2-18 years) with beta-TM. All the patients were in steady state and none had experienced clinical signs or symptoms of thrombosis. Highly elevated urinary levels of 11-dehydro-thromboxane B2 and significantly elevated plasma levels of thrombin-antithrombin III (TAT) complexes were observed to the same extent in TM children and adults. The levels of factor II were decreased while factors V, VII + X and plasminogen were within the normal range. The natural coagulation inhibitors, protein C (PC) and protein S (PS) were significantly decreased in all TM patients investigated, regardless of age, but the PS binding protein (C4bBP) and antithrombin III levels were normal. The frequency of other thrombophilic mutations was not increased. Thus, a chronic hypercoagulable state already exists in thalassaemia in childhood and may contribute to the cardiac and pulmonary anomalies and the thrombotic events which occur later.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10606878     DOI: 10.1046/j.1365-2141.1999.01758.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

Review 2.  Electrocardiographic Presentation, Cardiac Arrhythmias, and Their Management in β-Thalassemia Major Patients.

Authors:  Vincenzo Russo; Anna Rago; Andrea Antonio Papa; Gerardo Nigro
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-06-20       Impact factor: 1.468

3.  PAI-1 Study in Thalassemia Major Patients Receiving Multiple Blood Transfusion.

Authors:  Ashwini Kumar; H S Batra; Mithu Banerjee; S Bandyopadhyay; T K Saha; Pratibha Misra; Vivek Ambade
Journal:  Indian J Clin Biochem       Date:  2016-10-13

4.  A case of alpha-thalassemia-2 associated with pulmonary infarction.

Authors:  Seiji Hayashi; Hiroto Matsuoka; Teruo Harano; Keiko Harano; Hiroshi Nakahara; Isao Tachibana; Hiroshi Kida; Tomio Kawasaki; Shingo Kyotani; Yoshihiro Oka; Mitsunori Sakatani; Ichiro Kawase
Journal:  Lung       Date:  2006 Jul-Aug       Impact factor: 2.584

5.  Dominant beta-thalassemia with hemoglobin Hradec Kralove: enhanced hemolysis in the spleen.

Authors:  Shouichi Ohga; Akihiko Nomura; Hidetoshi Takada; Junko Kato; Hiroshi Ideguchi; Yukio Hattori; Masahiro Suda; Sachiyo Suita; Toshiro Hara
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

6.  Prevalence of thrombotic risk factors among beta-thalassemia patients from Western Iran.

Authors:  Zohreh Rahimi; Mandana Ghaderi; Ronald L Nagel; Adriana Muniz
Journal:  J Thromb Thrombolysis       Date:  2007-11-04       Impact factor: 2.300

7.  Subclinical haemorrhagic tendency exists in patients with β-thalassaemia major in early childhood.

Authors:  Abhishek Maiti; Amartya Chakraborti; Puranjoy Chakraborty; Sanjay Mishra
Journal:  Australas Med J       Date:  2012-02-29

Review 8.  Vascular complications after splenectomy for hematologic disorders.

Authors:  Shelley E Crary; George R Buchanan
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

Review 9.  Non-transfusion-dependent thalassemias.

Authors:  Khaled M Musallam; Stefano Rivella; Elliott Vichinsky; Eliezer A Rachmilewitz
Journal:  Haematologica       Date:  2013-06       Impact factor: 9.941

10.  Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders.

Authors:  Vichai Atichartakarn; Khanchit Likittanasombat; Suporn Chuncharunee; Pakorn Chandanamattha; Surapon Worapongpaiboon; Pantep Angchaisuksiri; Katcharin Aryurachai
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.